Every day, more lives are transformed all over the world – one healthy habit at a time. Read the latest about how Medifast and the OPTAVIA® movement is impacting people’s lives.
As a result of the recent Johns Hopkins, Bloomberg School of Medicine clinical study, Medifast's diabetic product line has demonstrated superb health management capabilities to combat obesity and improve overall health. Clinical Pharmacy Programs have the most concentrated obese and diabetic patient base that is in need of both pharmaceutical and nutritional solutions to ameliorate the devastating effects of diabetes. Patients using the Medifast/ Hi-Energy clinical meal replacements lost twice as much weight as those on a "food" program and were twice as compliant. Since many patients using Medifast also use other pharmaceuticals for conditions related to obesity, clinical pharmacy plays a unique role, particularly for the low-income patients who do not have health insurance.
"Over 15,000 physicians and millions of patients have improved their health using clinically proven Medifast/ Hi-Energy products and protocols, now with our chain drug partner we are offering another solution for the clinical pharmacist," says Brad MacDonald, CEO of Medifast and a seven-year retail veteran with chain drug management experience. "We are delighted to be the first in the nation to offer clinically proven nutrition solutions to improve health with an organization that is a leader in clinical pharmacy programs." Medifast currently provides support for over 100 licensed Hi-Energy Weight Control Centers nationwide and recently opened 11 corporate centers in Florida and Texas. To inquire about Hi-Energy Weight Control licensing opportunities contact Kellie Pizzico, VP of Operations, at telephone number 410-504-8162 or
This release contains forward-looking statements, which may involve known and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.
SOURCE: Medifast, Inc.
CONTACT: Jeremy Hunt, Medifast, +1-410-504-8196, or Ken Sgro, CEOcast,
Inc. for Medifast, +1-212-732-4300 x224
Web site: http://www.medifastdiet.com/